Table 1.
Baseline Characteristics by the Absence or Presence of Panic Symptoms (n=1195)
| Characteristics | No Panic Symptoms (n=1077) |
Panic Symptoms (n=118) |
Probability |
|---|---|---|---|
|
Sex, n (%)
Male Female |
722 (67) 355 (33) |
61 (51.7) 57 (48.3) |
0.001 |
| Median Age, y (IQR) | 49.9 (44.2-55.5) | 48.6 (40.8-54.4) | 0.005 |
|
Age, n (%)
< 50yo ≥ 50yo |
546 (50.7) 531 (49.3) |
67 (56.8) 51 (43.2) |
0.209 |
|
Race/Ethnicity, n (%)
African-American Caucasian/Othera |
917 (85.1) 160 (14.9) |
81 (68.6) 37 (31.4) |
0.000 |
|
Heroin/Cocaine Use, n (%)
Neither Heroin nor Cocaine Heroin Only Cocaine Only Both Heroin and Cocaine |
989 (91.8) 49 (4.6) 24 (2.2) 15 (1.4) |
100 (84.8) 12 (10.2) 2 (1.7) 4 (3.4) |
0.019 |
|
Depressive Symptoms, n (%)
No Yes |
963 (89.4) 114 (10.6) |
89 (75.4) 29 (24.6) |
0.000 |
|
Hazardous Drinking, n (%)
None Moderate Hazardous |
636 (59.1) 381 (35.4) 60 (5.6) |
64 (54.2) 46 (39.0) 8 (6.8) |
0.582 |
| Median Clinic Enrollment Time, y (IQR) | 8.3 (3.2-13.0) | 7.9 (2.9-11.4) | 0.107 |
| Median ACASI Follow-up Time, y (IQR) | 1.6 (1.1-1.9) | 1.5 (1.1-1.8) | 0.283 |
| Median CD4 count, n (IQR) | 444 (270-642) | 464.5 (322-664) | 0.151 |
| On Antiretroviral Therapy, n (%) | 984 (91.4) | 99 (83.9) | 0.008 |
| Medication Adherenceb, n (%) | 790 (77.8) | 77 (74.8) | 0.488 |
| Undetectable Viral Loadc, n (%) | 666 (66.3) | 77 (75.5) | 0.06 |
Abbreviations: IQR=interquartile range, y=year, ACASI-Audio computer assisted interview
a
Less than 2% of the Moore Clinic patient population self-identifies as Hispanic, Asian, Native-American, or Other therefore these racial/ethnic groups were included among the population self-identifying as Caucasian for the purposes of this analysis.
b
Medication adherence is assessed only in those on antiretroviral therapy (n=1119) and is defined as >90%.
c
Undetectable viral load is based on those individuals on ART who had an HIV-1 RNA available for analysis (n=1106) and is defined as <50 copies/mL.